Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05249426 · ClinicalTrials.gov registry record · Phase 1

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

A Phase 1 study of Head and Neck Squamous Cell Carcinoma (HNSCC), sponsored by Boehringer Ingelheim.

Active
Registry status
Phase 1
Development phase
48
Enrollment target
20
Study locations

NCT05249426 is a Phase 1 study of Head and Neck Squamous Cell Carcinoma (HNSCC) that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 48 participants, below the 260-participant average among 13 other Head and Neck Squamous Cell Carcinoma (HNSCC) trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05249426, a Phase 1 study of Head and Neck Squamous Cell Carcinoma (HNSCC), is active but no longer recruiting, sponsored by Boehringer Ingelheim.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
48 participants
Enrollment target
20
Study locations

Study Summary

With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined. This is a study for people for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out whether combining different medicines make tumours shrink. The tested medicines in this study are antibodies that act in different ways against cancer. BI 765063 and ezabenlimab may help the immune system fight cancer (checkpoint inhibitors). Cetuximab blocks growth signals and may prevent the tumour from growing. BI 836880 blocks the formation of new blood vessels that the tumour needs to grow. With amendments of the protocol, all participants receive cetuximab in addition to BI 765063 and ezabenlimab. Ezabenlimab treatment and any other assigned treatment are given no longer than 2 years. Previously, BI 765063 and ezabenlimab were also given alone, or in combination with chemotherapy, or with BI 836880. BI 765063, ezabenlimab, and BI 836880 are given as infusions into veins every 3 weeks. Cetuximab is given as an infusion every 1 or 2 weeks. Participants can stay in the study as long as they benefit from treatment and can tolerate it. They regularly visit the study site where doctors check participants' health and take note of any unwanted effects. The doctors also monitor the size of the tumour.

Conditions Studied

Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

  • DRUG Cetuximab
  • DRUG Ezabenlimab
  • DRUG BI 765063
  • DRUG BI 836880
  • OTHER Investigator´s Choice Chemotherapy

Study Locations (20)

Other

  • CTR Georges-François Leclerc - Dijon
  • CTR Leon Berard - Lyon
  • HOP Timone - Marseille
  • INS Curie - Paris
  • HOP Civil - Strasbourg
  • INS Claudius Regaud IUCT-Oncopole - Toulouse
  • Japanese Foundation for Cancer Research - Tokyo, Koto-ku
  • Hospital Sultan Ismail - Johor Bahru
  • Sarawak General Hospital - Kuching, Sarawak
  • ARKE SMO S.A. de C.V - Mexico City
  • FAICIC S de RL de C.V. - Veracruz
  • Investigacion Biomedica para el Desarrollo de Farmacos, S.A. de C.V. - Zapopan
  • ARENSIA Exploratory Medicine - Chisinau
  • Mandziuk Slawomir Specialist Medical Practice - Lublin
  • "Prof. Dr. Alexandru Trestioreanu" Oncology Institut - Bucharest
  • Institutul Oncologic "Prof. Dr. Ion Chiricuta" - Cluj-Napoca
  • Hospital Universitari Vall D Hebron - Barcelona
  • Hospital Duran i Reynals - L'Hospitalet de Llobregat
  • Hospital Clínico San Carlos - Madrid

California

  • Valkyrie Clinical Trials - Los Angeles

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2022-04-12
Est. Completion 2026-07-31
Phase Phase 1

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05249426

The ClinicalTrials.gov registry entry for NCT05249426 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 13 other Head and Neck Squamous Cell Carcinoma (HNSCC) trials with a reported enrollment target (82% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma (HNSCC) appearing as the primary indexed condition, and to 5 interventions - of which Cetuximab is the first listed.

NCT05249426 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, California.

Frequently Asked Questions

What is clinical trial NCT05249426 about?

NCT05249426 is a clinical study titled "A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer". With an amendment of the protocol, this study is only open to adults with head and neck cancer. Previously also adults with liver cancer joined. This is a study for people for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out whether...

What is the current status of trial NCT05249426?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-04-12. Estimated completion is 2026-07-31.

What conditions does trial NCT05249426 study?

This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma (HNSCC).

What interventions are being tested in trial NCT05249426?

The interventions under investigation include: Cetuximab (DRUG), Ezabenlimab (DRUG), BI 765063 (DRUG), BI 836880 (DRUG), Investigator´s Choice Chemotherapy (OTHER).

Who is sponsoring clinical trial NCT05249426?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05249426 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Squamous Cell Carcinoma (HNSCC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Squamous Cell Carcinoma (HNSCC)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.